Fundraising Fox
AtlasXomics
New Haven, US · Founded 2020 · Delaware corporation · 2 known investors
Find your way into AtlasXomics
Sign up to see every warm intro you have to AtlasXomics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the AtlasXomics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AtlasXomics develops spatial epigenomics tools, spanning chip fabrication, hardware, and bioinformatics, for researchers studying areas such as cancer and systems biology. The company serves scientific and clinical research customers with technology for analyzing epigenetic regulation.
Founders & leadership
GH
Gregory HoNamed on SEC filing
RA
Richard AnderssonNamed on SEC filing
Board
KW
Kenneth WangInvestor and entrepreneur (board member)
Investors · 2
Reported raises · per SEC filings
Form D private placements$6.2M disclosed across 3 rounds · 2020–2021
▶$3.9MraisedJan 2022 · 4 investors · BiotechnologyRule 506(b)
▶$3.9MraisedJan 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard AnderssonDirector
- John SteffensDirector
- Kenneth WangExecutive Officer, Director
- Gregory HoDirector
- Offering amount
- $8M
- Amount sold
- $3.9M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.8MraisedMar 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1.8MraisedMar 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth WangExecutive Officer, Director
- Gregory HoDirector
- Richard AnderssonDirector
- John SteffensDirector
- Offering amount
- $3.5M
- Amount sold
- $1.8M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$470KraisedJun 2020 · 2 investors · BiotechnologyRule 506(b)
▶$470KraisedJun 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gregory HoDirector
- Richard AnderssonDirector
- Kenneth WangExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $470K
- Minimum investment
- $25K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
10x Genomics10x Genomics offers single cell analysis technology, including its Flex assay and Flex Apex product, which use probe-based chemistry and plate-based multiplexing to profile fresh, frozen, and FFPE samples for researchers. The tools support applications in cancer, immunology, and neuroscience, enabling gene expression and multiomic profiling of cell surface protein, intracellular protein, and CRISPR guides.
IDbyDNAScalable, high throughput DNA sequencing platforms.
Active Motif
OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.
LatchBioLatch builds data infrastructure and software tools for biological computing, enabling researchers to program and automate biological discovery through high-throughput laboratory automation and machine learning.
Companies working in the same space as AtlasXomics.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $251.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $222K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does AtlasXomics do?
- AtlasXomics develops spatial epigenomics tools, spanning chip fabrication, hardware, and bioinformatics, for researchers studying areas such as cancer and systems biology. The company serves scientific and clinical research customers with technology for analyzing epigenetic regulation.
- Who are AtlasXomics's investors?
- AtlasXomics's investors include Connecticut Innovations, Elm Street Ventures.
- How much funding has AtlasXomics raised?
- AtlasXomics has disclosed $6.2M raised across 3 rounds.
- Where is AtlasXomics headquartered?
- AtlasXomics is headquartered in New Haven, US.